Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PERSANTINE (dipyridamole) is an oral small-molecule tablet approved in 1961 for cardiovascular indications, functioning as a platelet aggregation inhibitor and vasodilator. The drug is indicated for prophylaxis of thromboembolic complications in patients with prosthetic heart valves and as an adjunct to other antiplatelet agents. It works through inhibition of phosphodiesterase and adenosine uptake, promoting vasodilation and reducing platelet adhesion.
As LOE approaches, commercial teams face margin compression and declining market presence; job growth on this brand is limited and focused on transition planning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Persantine: Variation in Response Trial
Working on PERSANTINE offers limited career momentum; the product is in lifecycle decline with minimal linked job openings (0 identified) and faces intense competitive pressure in a mature market. Career value lies primarily in managing a legacy asset and executing transition strategies rather than in brand-building or commercial expansion.
Worked on PERSANTINE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.